A phase 3 clinical trial has produced positive results for cutaneous T-cell lymphoma (CTCL) patients.
The drug tested is called brentuximab vedotin (Adcetris). Specifically, the drug was created to treat the lesions which occur in about half of all patients diagnosed with CTCL.
Previously, the disease has had very few treatment options, and there is still no cure. So while the drug only has a potential to treat half of the patient population, it’s a positive step for the entire community.
Bob Lechleider, who is the senior vice president of Clinical Development at Seattle Genetics stated that- “The data from the ALCANZA trial provide compelling evidence that CTCL patients treated with Adcetris had superior outcomes across all primary and all secondary endpoints assessed in the study compared to patients in the control arm who were treated with a standard of care agent. These data demonstrate the potential of Adcetris to change the treatment landscape of CTCL.” All of the key endpoints of the trial proved to be highly statistically significant.
Clearly seeing the potential benefits of the treatment, a few days ago Seattle Genetics officially submitted data from the study to the FDA for approval.
Pending the FDA’s decision, cutaneous T-cell lymphoma patients may see brentuximab vedotin on the market in the near future.
Read more about this new potential treatment here!
